Crossmark

Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study

Crossref DOI link: https://doi.org/10.1016/j.eclinm.2024.102689

Published Print: 2024-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Tang, Bowen https://orcid.org/0000-0002-1391-2522
Sjölander, Arvid

Wastesson, Jonas W.

Maura, Géric

Blotiere, Pierre-Olivier

Szilcz, Máté

Mak, Jonathan K.L. https://orcid.org/0000-0003-4454-8580
Qin, Chenxi

Alvarsson, Michael

Religa, Dorota

Johnell, Kristina

Hägg, Sara
Funding

Funding for this research was provided by:

National Institute on Aging (1R01AG067996)

Karolinska Institutet

Swedish Research Council (2022-01608)

Swedish Research Council (2023-02223)

Riksbankens Jubileumsfond

National Institutes of Health
License Information

Text and Data Mining valid from 2024-07-01

Text and Data Mining valid from 2024-07-01

Version of Record valid from 2024-05-30
More Information

This article is maintained by: Elsevier

Article Title: Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study

Journal Title: eClinicalMedicine

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eclinm.2024.102689

Content Type: article

Copyright: © 2024 The Author(s). Published by Elsevier Ltd.

Document is current

Any future updates will be listed below